Bausch + Lomb Corporation (BLCO) CEO Joe Papa on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 06/08/22
Bausch + Lomb Announces Scientific Data on Latest Biotrue® Products to be Presented at American Optometric Association's Optometry's MeetingPRNewsWire • 06/06/22
New Social Media Campaign From Bausch + Lomb Aims to Raise Awareness that Cataracts Don't WaitPRNewsWire • 06/02/22
Bausch + Lomb Announces the U.S. Launch of Biotrue® Hydration Plus Multi-Purpose SolutionPRNewsWire • 06/02/22
Bausch + Lomb Receives Health Canada Approval of LUMIFY® Redness Reliever Eye DropsPRNewsWire • 05/24/22
Bausch + Lomb Corporation Files Financial Statements for the First Quarter of 2022PRNewsWire • 05/16/22
Bausch + Lomb Announces Participation at the RBC Capital Markets Global Healthcare ConferencePRNewsWire • 05/13/22
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious UveitisPRNewsWire • 05/12/22
Bausch Health And Bausch + Lomb Corporation Announce Closing Of Initial Public Offering Of Bausch + Lomb And Related Debt TransactionsPRNewsWire • 05/10/22
Bausch + Lomb stock opens with a slight gain, to value the company at about $6.5 billionMarket Watch • 05/06/22
The Wall Street Journal: Bausch + Lomb prices IPO at $18 a share, below expectationsMarket Watch • 05/05/22